Page 2 of 4, showing 50 records out of 191 total, starting on record 51, ending on 100
| Publication |
Category |
Year |
|
392. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. |
Breast Cancer |
2003 |
|
393. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. |
Breast Cancer |
2002 |
|
395. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. |
Breast Cancer |
2002 |
|
396. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. |
Breast Cancer |
2002 |
|
399. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2001) DHEA replacement therapy as source of androgens and estrogens at menopause, in: Genazani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, London, UK, Parthenon Publishing, pp 249-258. |
Breast Cancer |
2001 |
|
400. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. |
Breast Cancer |
2001 |
|
401. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. |
Breast Cancer |
2001 |
|
403. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. |
Breast Cancer |
2001 |
|
404. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. |
Breast Cancer |
2001 |
|
406. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. |
Breast Cancer |
2001 |
|
407. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. |
Breast Cancer |
2000 |
|
408. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. |
Breast Cancer |
2000 |
|
409. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. |
Breast Cancer |
2000 |
|
411. Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., Labrie, F. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol., 74: 45-56. |
Breast Cancer |
2000 |
|
412. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. |
Breast Cancer |
2000 |
|
414. The BRCA1 Exon 13 Duplication Screening Group. (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet., 67: 207-212. |
Breast Cancer |
2000 |
|
416. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. |
Breast Cancer |
1999 |
|
417. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. |
Breast Cancer |
1999 |
|
418. Hida, N., Poulin, R., Veilleux, R., Labrie, F. (1999) Differential androgen sensitivity is associated with clonal heterogeneity in steroid metabolism, ornithine decarboxylase regulation and IL-1alpha action in mouse mammary tumor cells. J. Steroid Biochem. Mol. Biol., 71: 71-81. |
Breast Cancer |
1999 |
|
420. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. |
Breast Cancer |
1999 |
|
421. Labrie, F.; (1999). EM-652: a pure anti-estrogen discovered and developed in Canada. The best hope for breast cancer prevention and treatment. Can. Breast Cancer Network, 4: Vol. 4, p. 7. |
Breast Cancer |
1999 |
|
422. Pelletier, G., Luu-The, V., Charbonneau, A., Labrie, F. (1999) Cellular localization of estrogen receptor beta messenger ribonucleic acid in cynomolgus monkey reproductive organs. Biol. Reprod., 61: 1249-1255. |
Breast Cancer |
1999 |
|
424. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1999) Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α⁄β heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927. |
Breast Cancer |
1999 |
|
425. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. |
Breast Cancer |
1998 |
|
426. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. |
Breast Cancer |
1998 |
|
428. Luo, S., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Prevention of development of dimenthylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11. |
Breast Cancer |
1998 |
|
429. Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, F. (1998) Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656. |
Breast Cancer |
1998 |
|
430. Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139: 2486-2492. |
Breast Cancer |
1998 |
|
431. Martel, C., Provencher, L., Li, X., St-Pierre, A., Leblanc, G., Gauthier, S., Mérand, Y., Labrie, F. (1998) Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol., 64: 199-205. |
Breast Cancer |
1998 |
|
432. Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M., Labrie, F. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol., 157: 433-442. |
Breast Cancer |
1998 |
|
433. Sourla, A., Martel, C., Labrie, C., Labrie, F. (1998) Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology, 139: 753-764. |
Breast Cancer |
1998 |
|
434. Tremblay, A., Tremblay, G.B., Labrie, C., Labrie, F., Giguère, V. (1998) EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and beta. Endocrinology, 139: 111-118. |
Breast Cancer |
1998 |
|
435. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1998) Ligand-independent activation of the estrogen receptors α and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res., 58: 877-881. |
Breast Cancer |
1998 |
|
436. Turgeon, C., Gingras, S., Carrière, M.C., Blais, Y., Labrie, F., Simard, J. (1998) Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. J. Steroid Biochem. Mol. Biol., 65: 151-162. |
Breast Cancer |
1998 |
|
438. Gauthier, S., Caron, B., Cloutier, J., Dory, Y.L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., 40: 2117-2122. |
Breast Cancer |
1997 |
|
439. Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Effect of dehydroepiandrosterone (DHEA) on bone mass, serum lipids, and dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 3387-3394. |
Breast Cancer |
1997 |
|
440. Luo, S., Martel, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Long-term inhibitory effects of a novel anti-estrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int. J. Cancer, 73: 735-739. |
Breast Cancer |
1997 |
|
441. Luo, S., Martel, C., Sourla, A., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int. J. Cancer, 73: 381-391. |
Breast Cancer |
1997 |
|
442. Luo, S., Sourla, A., Labrie, C., Bélanger, A., Labrie, F. (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444. |
Breast Cancer |
1997 |
|
443. Luo, S., Stojanovic, M., Labrie, C., Labrie, F. (1997) Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate (MPA) on estrone-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Int. J. Cancer, 73: 580-586. |
Breast Cancer |
1997 |
|
444. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S.M., Mérand, Y., Labrie, F. (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112. |
Breast Cancer |
1997 |
|
445. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S.M., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497. |
Breast Cancer |
1997 |
|
447. Sourla, A., Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Morphological changes induced by six-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology, 138: 5605-5617. |
Breast Cancer |
1997 |
|
448. Tremblay, G.B., Tremblay, A., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Labrie, F., Giguère, V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol., 11: 353-365. |
Breast Cancer |
1997 |
|
450. Blais, Y., Gingras, S., Haagensen, D.E., Labrie, F., Simard, J. (1996). Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol. Cell. Endocrinol., 121: 11-18. |
Breast Cancer |
1996 |
|
451. Blais, Y., Zhao, C., Huber, M., Audette, M., Labrie, F., Poulin, R. (1996) Growth-independent induction of spermidine transport by IL-4 and IL-13 in ZR-75-1 human breast cancer cells. Int. J. Cancer, 67: 532-538. |
Breast Cancer |
1996 |
|
452. Couch, F.J., Rommens, J.M., Neuhausen, S.L., Bélanger, C., Dumont, M., Abel, K., Bell, R., Berry, S., Bogden, R., Cannon-Albright, L., Farid, L., Frye, C., Hattier, T., Janecki, T., Jiang, P., Kehrer, R., Leblanc, J.F., McArthur-Morrison, J., McSweeney, D., Miki, Y., Peng, Y., Samson, C., Schroeder, M., Snyder, S.C., Stringfellow, M., Stroup, C., Swedlund, B., Swensen, J., Teng, D., Thakur, S., Tran, T., Tranchant, M., Welver-Feldhaus, J., Wong, A.K.C., Sjoziua, J., Labrie, F., Skolnick, M.H., Goldgar, D.E., Kamb, A., Weber, B.L., Tavtigian, S.V., Simard, J. (1996) Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. Genomics, 36: 86-99. |
Breast Cancer |
1996 |
|
453. Durocher, F., Shattuck-Eidens, D., McClure, M., Labrie, F., Skolnick, M.H., Goldgar, D.E., Simard, J. (1996) Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum. Mol. Genet., 5: 835-842. |
Breast Cancer |
1996 |
|
454. Poirier, D., Mérand, Y., Labrie, C., Labrie, F. (1996) D-Ring alkylamide derivatives of estradiol: Effect on ER-binding affinity and antiestrogenic activity. Bioorg. Med. Chem. Lett., 6: 2537-2542. |
Breast Cancer |
1996 |
|
455. Tavtigian, S.V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., Belanger, C., Bell, R., Berry, S., Bogden, R., Chen, Q., Davis, T., Dumont, M., Frye, C., Hattier, T., Jammulapati, S., Janecki, T., Jiang, P., Kehrer, R., Leblanc, J.-F., Mitchell, J.T., McArthur-Morrison, J., Nguyen, K., Peng, Y., Samson, C., Schroeder, M., Snyder, S.C., Steele, L., Stringfellow, M., Stroup, C., Swedlund, B., Swensen, J., Teng, D., Thomas, A., Tran, T., Tran, T., Tranchant, M., Weaver-Feldhaus, J., Wong, A.K.C., Shizuya, H., Eyfjord, J.E., Cannon-Albright, L., Labrie, F., Skolnick, M.H., Weber, B., Kamb, A., Goldgar, D.E. (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet., 12: 333-337. |
Breast Cancer |
1996 |